MidCap Financial

Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.

Arq is an environmental technology company that focuses on transforming mining waste into high-value advanced carbon products. By leveraging innovative technologies, Arq aims to contribute to a cleaner and safer world while actively reducing its environmental footprint. The company's operations emphasize sustainability and resource recovery, positioning it as a key player in the oil and energy sector. Through its commitment to environmental responsibility, Arq strives to create solutions that not only enhance the value of mining byproducts but also promote a more sustainable future.

Regis Corporation is a prominent owner, operator, and franchisor of hairstyling and hair care salons, headquartered in Minneapolis, Minnesota. The company operates in the United States, the United Kingdom, Canada, and Puerto Rico, managing over 8,600 salons across various brands, including SmartStyle, Supercuts, Cost Cutters, Roosters, and First Choice Haircutters. Regis provides a range of services such as haircutting, styling, hair coloring, and other beauty treatments, along with the sale of hair care products. In addition to salon services, the company offers digital solutions like OpenSalon Pro, a cloud-based salon management system, and mobile applications for booking and check-in services. Founded in 1922, Regis also operates accredited cosmetology schools and employs more than 41,000 individuals worldwide.

Xtant Medical develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons worldwide. Its portfolio includes biomaterial products like OsteoSponge, OsteoSelect Plus DBM Putty, and 3Demin allografts, along with spinal implant systems such as Certex, Spider, Axle, and Fortex. The company's offerings facilitate spinal fusion in complex spine procedures.

OrthoPediatrics is a specialized medical device company focused on developing and manufacturing orthopedic implants and instruments specifically for pediatric orthopedic surgeons. The company is dedicated to enhancing the treatment of children's orthopedic conditions through the invention and distribution of innovative, anatomically appropriate implants and unique instrumentation. Its product offerings include various solutions such as PediLoc, PediPlates, Cannulated Screws, and specialized nails for pediatric use. OrthoPediatrics emphasizes the importance of creating devices that cater to the unique anatomical needs of small stature patients, ensuring both safety and efficacy in surgical procedures. The company's commitment to improving surgical experiences is exemplified by its QCR technology, which operates with minimal noise and vibration, thereby reducing patient anxiety during treatments.

Express Wash Concepts operates a chain of car washing facilities dedicated to delivering exceptional customer service and high-quality vehicle cleaning experiences. The company focuses on providing comprehensive maintenance and cleaning services for vehicle owners, specializing in car washing and vacuum cleaning. By prioritizing customer satisfaction, Express Wash Concepts aims to create a reliable and efficient environment for customers to care for their vehicles.

Strata Skin Sciences is a medical technology company focused on dermatology, developing, marketing, and distributing devices for treating skin conditions. Its product portfolio centers on the XTRAC excimer laser and VTRAC lamp systems used to treat psoriasis, vitiligo, eczema, and related disorders. The company operates two segments: Dermatology Recurring Procedures, deriving revenue from ongoing use of its devices by dermatologists, and Dermatology Procedures Equipment, from sales of equipment. Distribution is international through distributors and domestic direct sales to physicians. Headquartered in Horsham, Pennsylvania, Strata Skin Sciences traces its origins to 1989.

Marco Capital, Inc. is a trade finance platform headquartered in Miami, Florida, that aims to provide small and medium-sized exporters from Latin America with access to working capital. Established in 2019, the platform facilitates investments in short-term trade finance receivables between Latin American exporters and U.S. importers. It promotes paperless processes, allowing users to upload documents and invoices seamlessly. The platform also incorporates support from industry experts and leverages artificial intelligence to streamline financing services and trade operations. Marco Capital focuses on simplifying the financing experience for businesses, enabling them to save time and foster growth.

Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Surmodics is a healthcare technology company that specializes in surface modification and in vitro diagnostic technologies. It develops and commercializes highly differentiated vascular intervention medical devices designed to address unmet clinical needs.

Carbon6 is a provider of a comprehensive software suite designed for online entrepreneurs operating within the Amazon marketplace. The company focuses on simplifying e-commerce business management by offering tools for business intelligence, inventory management, and advertising solutions. In addition to its software offerings, Carbon6 also acquires, develops, and integrates various technologies that support e-commerce merchants, enhancing their operational success. The company further supports entrepreneurs by providing educational programs, research tools, and resources aimed at improving product listings and overall profitability. Through its integrated solutions, Carbon6 aims to enable e-commerce businesses to achieve their goals and foster growth throughout their entrepreneurial journey.

Carbon6 is a provider of a comprehensive software suite designed for online entrepreneurs operating within the Amazon marketplace. The company focuses on simplifying e-commerce business management by offering tools for business intelligence, inventory management, and advertising solutions. In addition to its software offerings, Carbon6 also acquires, develops, and integrates various technologies that support e-commerce merchants, enhancing their operational success. The company further supports entrepreneurs by providing educational programs, research tools, and resources aimed at improving product listings and overall profitability. Through its integrated solutions, Carbon6 aims to enable e-commerce businesses to achieve their goals and foster growth throughout their entrepreneurial journey.

TELA Bio is a medical technology company specializing in soft tissue reconstruction. It designs, develops, and markets the OviTex Reinforced Tissue Matrix portfolio for hernia repair and abdominal wall reconstruction, as well as OviTex PR Reinforced Tissue Matrix for plastic and reconstructive surgery and OviTex for laparoscopic and robotic procedures. The reinforced matrices are derived from ovine rumen with polypropylene fiber and are intended to address unmet needs in soft tissue repair while emphasizing preservation of anatomy and minimizing long-term exposure to permanent synthetic materials. The company markets its products through a single direct sales force, principally in the United States. Founded in 2012 and headquartered in Malvern, Pennsylvania.

Forge Biologics, Inc. is a contract development and manufacturing organization (CDMO) specializing in gene therapies and genetic medicines. Founded in 2019 and based in Columbus, Ohio, the company focuses on developing and manufacturing therapeutics, particularly for viral vector gene therapies aimed at treating genetic diseases. Notably, it offers a novel approach combining adeno-associated virus (AAV) and umbilical cord transplant to address infantile Krabbe disease, a severe neurodegenerative disorder. Additionally, Forge Biologics collaborates with scientists, physicians, biotech and pharmaceutical companies, and patient groups to facilitate the progression of gene therapy programs from preclinical development through to clinical and commercial-scale manufacturing. The company is committed to enabling access to transformative medicines for patients suffering from rare genetic diseases.

Aterian is a platform specializing in consumer product development and management. Established in 2014, it operates globally with offices across North America, Europe, Asia, and Australia. Aterian builds, acquires, and partners with brands to create top-selling products across categories like home appliances, beauty products, and electronics. It leverages proprietary software and agile supply chains for efficient product creation.

UpStack is a company that specializes in providing customized cloud infrastructure solutions through its innovative SaaS-based colocation procurement platform. The platform aids businesses in making informed decisions by utilizing pricing normalization technology, which equalizes pricing across various data center vendors. This approach eliminates guesswork and errors, allowing IT professionals, systems integrators, and consultants to efficiently discover, price, and procure colocation services. By streamlining the procurement process, UpStack significantly reduces both the time and costs typically associated with traditional methods, making it easier for businesses of all sizes to navigate their infrastructure challenges.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Modern Campus is a software company specializing in student lifecycle management solutions tailored for higher education institutions. Its SaaS platform focuses on managing continuing education and non-degree programs, catering to students outside the traditional full-time degree framework. By enhancing digital engagement, Modern Campus aims to improve the overall student experience, enabling institutions to increase enrollment, streamline administrative processes, and efficiently oversee their educational offerings.

Xtant Medical develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons worldwide. Its portfolio includes biomaterial products like OsteoSponge, OsteoSelect Plus DBM Putty, and 3Demin allografts, along with spinal implant systems such as Certex, Spider, Axle, and Fortex. The company's offerings facilitate spinal fusion in complex spine procedures.

LendingPoint LLC is a financial technology company established in 2014, headquartered in Kennesaw, Georgia, with additional offices in New York and Nevada. The company specializes in online consumer lending, offering a cloud-based platform that utilizes predictive risk algorithms to provide personal loans for various purposes, including debt consolidation, home improvement, and medical expenses. Additionally, LendingPoint offers financing solutions through its LendingPoint Merchant Solutions platform, catering to merchants, service providers, and medical institutions. The company's innovative lending operating system enhances credit approval processes for e-commerce and point-of-sale purchases while employing advanced fraud prevention and risk management techniques to create diverse financing opportunities across the credit spectrum.

Medexus Pharmaceuticals is a specialty pharmaceutical company focused on the North American market. It develops, markets, and distributes a portfolio of therapies addressing rare diseases, autoimmune conditions, pediatric needs, oncology, and allergy. The company’s products include Rasuvo and Metoject (methotrexate) for rheumatoid arthritis and other autoimmune diseases; IXINITY for Hemophilia B; Rupall for seasonal and perennial allergic rhinitis and chronic spontaneous urticaria; Cuvposa for sialorrhea in children with neurologic conditions; Gliolan for intraoperative visualization of brain tumors; and Treosulfan as a conditioning agent before stem cell transplantation. Its operations span Canada and the United States, supported by a North American commercial platform that sells to wholesalers, distributors, healthcare facilities, and specialty pharmacies. Originally known as Pediapharm, the company rebranded as Medexus in 2018 and is based in Verdun, Canada.

Digital Reasoning Systems, Inc. is a developer of an artificial intelligence cognitive computing platform that specializes in processing and organizing unstructured data into meaningful insights for businesses. Founded in 2000 and based in Franklin, Tennessee, with additional offices in New York, Washington, D.C., and London, the company offers its primary product, Synthesys, which utilizes advanced features such as natural language processing, entity resolution, and link analysis. This platform is designed to automatically categorize, link, retrieve, and profile unstructured data, providing critical intelligence and insights for industries including finance, healthcare, and legal sectors. Digital Reasoning's solutions support intelligence analysts in both government and commercial markets, enhancing their ability to visualize connections within data sets and address risks and threats effectively. The company maintains strategic partnerships to enhance its offerings and expand its reach in the market.

Arboretum Investment Advisors, LLC specializes in providing financing and investment advisory services focused on fundamental capital assets that are essential to middle-market companies globally. The firm manages funds that offer asset-backed financing, emphasizing non-correlated, income-producing investment strategies to diversify investor portfolios. In addition to financing, Arboretum is involved in asset management and asset servicing, catering specifically to the needs of its clients in the middle-market sector.

Protagonist Therapeutics, Inc., established in 2006 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies to address unmet medical needs in hematology and gastroenterology. The company's pipeline includes PTG-300, an injectable hepcidin mimetic in Phase II trials for beta-thalassemia; PTG-200, a completed Phase I antagonist peptide candidate for moderate-to-severe Crohn’s disease; and PN-943, an oral integrin antagonist in Phase I trials for inflammatory bowel disease. Protagonist has a licensing and collaboration agreement with Janssen Biotech for PTG-200's development and commercialization. The company's proprietary platform enables the discovery of novel constrained peptide-based drug candidates targeting protein-protein interactions.

Sight Sciences, Inc. is a medical device company specializing in the development and commercialization of technologies for the treatment of eye diseases, particularly glaucoma and dry eye conditions. Headquartered in Menlo Park, California, with an additional office in Southlake, Texas, the company offers the OMNI Surgical System, which allows surgeons to perform canaloplasty and trabeculotomy through a single device and corneal incision, thereby reducing intraocular pressure in patients with primary open-angle glaucoma. Additionally, Sight Sciences provides the TearCare System, a wearable eyelid technology that delivers targeted and adjustable thermal energy to the meibomian glands, addressing conditions like meibomian gland dysfunction and dry eye. Founded in 2010, the company aims to improve patient outcomes through innovative approaches in ophthalmic care.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Organogenesis is a regenerative medicine company specializing in developing, manufacturing, and commercializing advanced wound care products such as Apligraf for venous leg ulcers and diabetic foot ulcers. The company also offers surgical and sports medicine products like NuShield and PuraPly AM. Organogenesis serves hospitals, wound care centers, and physician offices through direct sales representatives.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

Sonar Entertainment, Inc. is an independent entertainment studio based in Los Angeles, California, with additional offices in Toronto, Miami, London, Sydney, and Singapore. Founded in 1979 and formerly known as RHI Entertainment, the company specializes in the development, production, financing, and distribution of television series, miniseries, and movies for both domestic and international audiences. Sonar offers a diverse range of content across various genres, including action, comedy, drama, horror, and reality. It also distributes a library of titles and sells DVDs and digital media products online. With a commitment to nurturing creative talent, Sonar provides a comprehensive platform that supports the entire production process while ensuring broad access to its content through collaborations with local networks and producers.

Kashable provides a financial wellness platform for large employers as an employer-sponsored voluntary benefit. The platform enables employees to apply for loans online and repay automatically via payroll deductions, offering a structured option to manage high debt and unexpected expenses. It emphasizes socially responsible credit and is positioned as a workplace-provided benefit rather than a consumer loan. Founded in 2013 and based in New York.

The Credit Junction is a New York-based company that operates an asset-based lending platform, founded in 2014. It specializes in providing working capital, growth, and supply chain financing solutions to small and mid-size enterprises, particularly suppliers, distributors, and manufacturers with revenues between $5 million and $50 million. The Credit Junction leverages technology and data intelligence alongside traditional credit metrics to offer loans of up to $7.5 million. Its platform streamlines the application, vetting, and approval process for borrowers, who can upload relevant documents through dedicated portals. The company has strategic partnerships with several firms and serves clients in the United States and Canada.

ZPower, LLC is a developer and manufacturer of rechargeable silver-zinc micro batteries, primarily serving the hearing aid, medical device, and portable electronics markets. Founded in 1996 and headquartered in Camarillo, California, the company specializes in advanced battery technology that enhances product development for manufacturers and improves performance for end-users. ZPower's offerings include various models of rechargeable micro batteries, as well as charging systems specifically designed for hearing aids. The company's innovative solutions aim to simplify product development processes, accelerate time-to-market, and provide a sustainable alternative for users. In March 2020, ZPower filed for reorganization under Chapter 11 in the U.S. Bankruptcy Court, indicating challenges in its operational journey.

Partner Therapeutics is an oncology-focused company dedicated to developing and commercializing approved and late-stage cancer therapies. Its portfolio spans primary treatments to supportive care, with a notable focus on Leukine for white blood cell growth.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Founded in 1980, Sarepta Therapeutics is a biopharmaceutical company headquartered in Cambridge, Massachusetts. It specializes in the discovery and development of precision genetic medicine to treat rare diseases, focusing on gene therapy, RNA-targeted exon skipping, and gene editing.

Elutia is a commercial-stage regenerative medicine company dedicated to advancing surgical outcomes for patients receiving implantable medical devices. The company focuses on developing a new generation of differentiated products through its proprietary tissue processing platforms, resulting in a portfolio of advanced regenerative medical products that closely mimic natural biological materials. Elutia operates across several segments, including Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment generating the majority of its revenue. Its products aim to address unmet clinical needs by promoting healthy tissue formation and reducing complications associated with medical device implants, such as scar-tissue formation and capsular contraction.

Founded in 2011, Fundation empowers small businesses by connecting them with financial institutions for working capital and growth financing. It offers outsourced lending programs, point-of-sale financing solutions, and digital credit lending platforms.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

IOU Financial operates an online commercial lending platform serving small businesses across North America. It originates, sells, and services loans for various sectors such as medical practices, retail stores, restaurants, and manufacturing companies. With over $200 million funded in small business loans, IOU Financial has extensive experience helping businesses secure capital to seize growth opportunities.

Spectra7 Microsystems Inc. is an analog semiconductor company based in San Jose, California, with operations in Canada and China. It specializes in providing high-performance solutions that deliver exceptional bandwidth, speed, and resolution, catering to the needs of leading consumer electronics manufacturers. The company's product offerings include virtual reality components, such as the VR7050, which facilitates lightweight and ultra-thin interconnects for gesture recognition and motion control. Additionally, it produces augmented reality solutions, including the AR-Connect integrated cable and chipset line, designed for AR vision systems and wearable devices. Spectra7 also develops high-bandwidth interconnects for data centers and provides USB 3.1 solutions for ultra-thin laptops, tablets, and mobile devices. Its innovations are aimed at enhancing connectivity across various markets, including virtual reality, augmented reality, and industrial design.

The Spectranetics Corporation specializes in the development, manufacturing, and distribution of single-use medical devices for minimally invasive cardiovascular procedures. Its portfolio includes laser and aspiration catheters, scoring balloon catheters, and drug-coated balloon catheters, used to cross, prepare, and treat arterial blockages in the legs and heart. Additionally, the company offers products for the removal of pacemaker and defibrillator cardiac leads, and provides laser systems for various cardiovascular procedures. Spectranetics sells its products directly and through distributors worldwide, with a focus on innovation to meet the demands of complex cardiac lead removal and vascular intervention procedures. Headquartered in Colorado Springs, Colorado, the company operates as a subsidiary of Philips Holding USA Inc.

Flexion Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for managing musculoskeletal conditions. Its flagship product, ZILRETTA, is an intra-articular injection used for knee osteoarthritis pain management in the United States.

Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company headquartered in Raleigh, North Carolina, dedicated to addressing the needs of patients with chronic pain and opioid dependence. Founded in 1997, the company focuses on the development and commercialization of innovative pharmaceutical products, leveraging its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology. This technology allows for the creation of small erodible polymer films designed for effective application to the buccal mucosa. BioDelivery Sciences offers a range of products, including BELBUCA, a buprenorphine buccal film for chronic pain management, and BUNAVAIL, a buprenorphine and naloxone buccal film aimed at treating opioid dependence. Additionally, it provides ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients, and Symproic, which treats opioid-induced constipation in adults with chronic pain. The company's focus on novel drug delivery methods enables it to address important unmet medical needs in pain management and addiction medicine.

Staffing 360 Solutions is a company operating in the international staffing sector, focusing on professional placement and staffing services across various industries. It employs a buy-and-build strategy by acquiring both domestic and international staffing organizations. The company is organized into three business streams: Professional Staffing, Commercial Staffing, and Employer of Record. Staffing 360 Solutions primarily supports sectors such as accounting and finance, information technology, engineering, administration, and commercial disciplines. By integrating acquired firms, the company aims to enhance its service offerings and expand its market presence globally.

Aventine Renewable Energy, Inc. is a prominent producer of corn-based fuel-grade ethanol and related by-products, primarily serving as a gasoline additive. The company markets and distributes its products to leading energy and food companies across the United States and internationally. Aventine's production facilities create low-carbon renewable fuels, significantly contributing to reducing dependence on foreign oil and minimizing environmental pollutants. By generating additional revenue through the sale of bio-products and co-products, Aventine effectively offsets a substantial portion of its corn costs, reinforcing its position as a key player in the renewable energy sector.

Larimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. Its lead compound, CTI-1601, is currently in Phase 1 clinical trials as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.

Omeros discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, immunologic disorders, cancers, and addictive/compulsive disorders.

Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering therapies for rare and orphan diseases. It specializes in oral pharmacological chaperones—small molecules that bind, stabilize, and enhance activity of misfolded enzymes—to treat lysosomal storage disorders such as Fabry and Pompe disease, and it explores combination approaches with enzyme replacement therapy. The company maintains a growing pipeline targeting additional lysosomal diseases, including Gaucher, and collaborates with academic and clinical partners to advance its programs. Amicus was founded in 2002 and is headquartered in Cranbury, New Jersey.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

Stellar Pharmaceuticals Inc. is an innovative Canadian Health Care Company focused on providing healthcare professionals and their patients.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Kashable provides a financial wellness platform for large employers as an employer-sponsored voluntary benefit. The platform enables employees to apply for loans online and repay automatically via payroll deductions, offering a structured option to manage high debt and unexpected expenses. It emphasizes socially responsible credit and is positioned as a workplace-provided benefit rather than a consumer loan. Founded in 2013 and based in New York.